Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GATHER: Tafenoquine vs Primaquine for P. vivax Malaria
NCT02216123Phase 3Completed
- Sponsor
- GSK
- Start
- Apr 2015
- Primary completion
- Nov 2016
- Modality
- Classical Binding Small Molecules, Nucleic Acid-Directed Small Molecules
- Countries
- 6
01
Overview
Phase 3, randomised, double-blind trial of tafenoquine in Plasmodium vivax malaria (2 arms), sponsored by GSK. Primary endpoints: Percentage of Participants With Clinically Relevant Hemolysis and Percentage of Female Participants With Moderate Glucose-6 Phosphate Dehydrogenase (G6PD) Deficiency Experiencing Clinically Relevant Hemolysis. Started Apr 2015; status: completed.
02
Drugs
tafenoquine
03
Conditions
Plasmodium vivax malaria
Beyond the preview
Go deeper on NCT02216123.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02216123.